World-Renowned Spinal Cord Injury Researcher and StemCyte Collaborator Wise Young to Participate in Presentation by Company’s Chairman

ARCADIA, Calif., Feb. 26, 2008 – StemCyte Inc. today announced that Kenneth J. Giacin, chairman and chief executive officer, will present an overview of the company and its marketed umbilical cord blood stem cell therapies today at the 3rd Annual Stem Cell Summit in New York City. 

In addition, the company said Rutgers University’s  Wise Young, M.D., Ph.D., a world-renowned spinal cord researcher and StemCyte collaborator, will participate in the presentation. Dr. Young will discuss recent collaborative activities between StemCyte and his laboratory at the W.M. Keck Center in pursuit of novel therapeutics for the treatment of stroke and spinal cord injury.

The 3rd Annual Stem Cell Summit will take place at the Hilton New York.  For information about the conference, visit www.stemcellsummit.com.

About StemCyte

StemCyte Inc. is a global leader in stem cell therapeutics with a marketed umbilical cord blood stem cell transplantation product. The company’s proprietary plasma-depleted cord blood stem cell products have been used to cure hundreds of patients with life-threatening diseases.  With its partners, StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies and has the largest clinical study for using unrelated cord blood transplantation for thalassemia, one of the most common genetic diseases in the world. The company operates one of two, and the only commercial cord blood bank in the world, dually accredited by AABB (formerly the American Association of Blood Banks) and Foundation for the Accreditation of Cellular Therapy (FACT). StemCyte is the only private company contracted by the Federal Government to establish a National Cord Blood Inventory. For more information, visit www.stemcyte.com.